Exelixis

EXELApproved

Alameda, United StatesFounded 1994exelixis.com

Exelixis has evolved into a multi-platform cancer company over three decades, transitioning from early-stage development to commercial success with approved oncology treatments. The company operates through both small molecule discovery and biotherapeutics platforms, with a robust pipeline including next-generation TKIs and innovative biologics. Their strategic approach combines internal R&D capabilities with external partnerships to advance multiple clinical programs across various cancer types.

Market Cap

$10.7B

Founded

1994

Focus

Small Molecules

EXEL · Stock Price

USD 41.27+19.39 (+88.62%)

Historical price data

AI Company Overview

Technology Platform

Multi-platform approach combining small molecule discovery targeting kinase pathways (MET/VEGFR/AXL/RET) with biotherapeutics including bispecific antibodies and antibody-drug conjugates for cancer treatment.

Pipeline Snapshot

113

113 drugs in pipeline, 10 in Phase 3

Drug	Indication	Stage
Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Plac...	Medullary Thyroid Cancer	Approved
XL184 + Placebo	Thyroid Cancer	Phase 3
Cabozantinib + Nivolumab + Ipilimumab + Cabozantinib-matched placebo	Renal Cell Carcinoma	Phase 3
Cabozantinib tablets + Placebo tablets	Hepatocellular Carcinoma	Phase 3
XL092 + Nivolumab + Sunitinib Malate	Non-Clear Cell Renal Cell Carcinoma	Phase 3

Funding History

Total raised: $108M

IPO$42MUndisclosedApr 12, 2000

Series C$30MUndisclosedJun 15, 1997

Series B$20MUndisclosedJun 15, 1996

Series A$12MUndisclosedJun 15, 1995

FDA Approved Drugs

CABOMETYXNDAApr 25, 2016

COMETRIQNDANov 29, 2012

Opportunities

Multiple late-stage clinical programs provide near-term catalysts, with recent FDA acceptance of zanzalintinib NDA for colorectal cancer representing significant commercial opportunity.

The company's multi-platform approach and strategic partnerships enable expansion across various cancer types and combination strategies.

Risk Factors

Clinical development risks across multiple Phase 3 programs, competitive pressure in oncology markets, and regulatory approval uncertainties.

Commercial success depends on successful differentiation from existing cancer therapies and effective market penetration strategies.

Competitive Landscape

Exelixis competes against major pharmaceutical companies and biotech firms in oncology, differentiating through multi-kinase inhibitor expertise, next-generation compound development, and strategic combination approaches. The company's established commercial presence and pipeline breadth provide competitive advantages in the crowded cancer therapeutics space.

Publications

Patents

Pipeline

113

FDA Approvals